Mesenchymal stem cells (MSCs) exhibit as adherent fibroblast-like cells and could differentiate into various tissue lineages. MSCs have be isolated from many human tissues, including bone marrow, adipose, placenta, umbilical cord, amniotic fluid and dental pulp. 

    In clinical settings, MSCs display broad and potent regenerative and immune-modulatory properties as medicinal therapeutics. With the ability to differentiate into several mesenchymal lineages, MSCs have been employed in repair of Osteogenesis Imperfecta (OI), cartilage defects and degenerative arthritis. Moreover, MSCs can adopt an immune-suppressive phenotype which in co-infusion may significantly prevent the incidence of life-threatening graft versus host disease (GVHD). 

    MSCs expansion in therapeutic settings demands cell productivity and scalability through various culture conditions to meet GMP guidelines. Human platelet lysate (hPL) is a viable and valuable serum substitute for ex vivo expansion of MSCs.